Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) [Phase 1]

View source ↗

Summary

Phase 1 study of pembrolizumab (Keytruda) in relapsed or refractory primary mediastinal large B-cell lymphoma has completed enrollment, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma, B-Cell | Phase 1 | Status: COMPLETED | Results posted: 2025-04-06